Jéssica Rabelo Bezerra

Dr. Jéssica Rabelo Bezerra

Universidade Federal do Ceará, Fortaleza, Ceará, Brazil
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
Jéssica Rabelo BezerraJéssica Rabelo Bezerra
Jéssica Rabelo Bezerra
TNTyciane de Souza Nascimento
Tyciane de Souza Nascimento
JTJuliete Tavares
Juliete Tavares
MAMayara Sandrielly Soares de Aguiar
Mayara Sandrielly Soares de Aguiar
MMMaiara Virgínia Viana Maia
Maiara Virgínia Viana Maia
GAGeanne Matos Andrade
Geanne Matos Andrade

17 June 2023 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
JPJuliana Fernandes Pereira
Juliana Fernandes Pereira
JNJuliana Catharina de Sousa Neves
Juliana Catharina de Sousa Neves
AFAnalu Aragão Fonteles
Analu Aragão Fonteles
Jéssica Rabelo BezerraJéssica Rabelo Bezerra
Jéssica Rabelo Bezerra
RPRayssa Costa Pires
Rayssa Costa Pires
GAGeanne Matos Andrade
Geanne Matos Andrade

Verified
Journal Article
Open access
PDF file
PAPedro Everson Alexandre de Aquino
Pedro Everson Alexandre de Aquino
Jéssica Rabelo BezerraJéssica Rabelo Bezerra
Jéssica Rabelo Bezerra
TNTyciane de Souza Nascimento
Tyciane de Souza Nascimento
JTJuliete Tavares
Juliete Tavares
Ítalo Rosal LustosaÍtalo Rosal Lustosa
Ítalo Rosal Lustosa
GVGLAUCE VIANA
GLAUCE VIANA
The N-methyl-(2S,4R)-trans-4-hydroxy-l-proline-enriched fraction (NMP) from Sideroxylon obtusifolium was evaluated as a neuroprotective agent in the intracerebroventricular (icv) pilocarpine (Pilo) model. To this aim, male mice were subdivided into sham (SO, vehicle), Pilo (300 µg/1 µL icv, followed by the vehicle per os, po) and NMP-treated groups (Pilo 300 µg/1 µL icv, followed by 100 or 200 mg/kg po). The treatments started one day after the Pilo injection and continued for 15 days. The effects of NMP were assessed by characterizing the preservation of cognitive function in both the Y-maze and object recognition tests. The hippocampal cell viability was evaluated by Nissl staining. Additional markers of damage were studied—the glial fibrillary acidic protein (GFAP) and the ionized calcium-binding adaptor molecule 1 (Iba-1) expression using, respectively, immunofluorescence and western blot analyses. We also performed molecular docking experiments revealing that NMP binds to the γ-aminobutyric acid (GABA) transporter 1 (GAT1). GAT1 expression in the hippocampus was also characterized. Pilo induced cognitive deficits, cell damage, increased GFAP, Iba-1, and GAT1 expression in the hippocampus. These alterations were prevented, especially by the higher NMP dose. These data highlight NMP as a promising candidate for the protection of the hippocampus, as shown by the icv Pilo model.

20 November 2024 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
JTJuliete Tavares
Juliete Tavares
AOAlfaete Vieira Oliveira
Alfaete Vieira Oliveira
TNTyciane de Souza Nascimento
Tyciane de Souza Nascimento
JGJessica Maria Pessoa Gomes
Jessica Maria Pessoa Gomes
APAna Caroline Barros Parente
Ana Caroline Barros Parente
GAGeanne Matos Andrade
Geanne Matos Andrade

4 October 2024 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
JTJuliete Tavares
Juliete Tavares
AOAlfaete Vieira Oliveira
Alfaete Vieira Oliveira
TNTyciane de Souza Nascimento
Tyciane de Souza Nascimento
MAMayara Sandrielly Soares de Aguiar
Mayara Sandrielly Soares de Aguiar
JPJose Regis de Paiva
Jose Regis de Paiva
GAGeanne Matos Andrade
Geanne Matos Andrade

1 April 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
GAGeanne Matos Andrade
Geanne Matos Andrade
Jéssica Rabelo BezerraJéssica Rabelo Bezerra
Jéssica Rabelo Bezerra
TNTyciane de Souza Nascimento
Tyciane de Souza Nascimento
JTJuliete Tavares
Juliete Tavares
AAAmanda Aragão Alves
Amanda Aragão Alves
MCMarta Regina Santos Do Carmo
Marta Regina Santos Do Carmo
Alzheimer's disease (AD) is an age‐related neurodegenerative disease characterized by a progressive decline in cognitive functions. Adenosine receptors play a pivotal role in disease progression, however, adenosine A3 receptors are understudied and their effects vastly unknown. We now investigated the effects of the activation of adenosine A3 receptors on memory deficits and oxidative damage in a mouse model of streptozotocin‐induced experimental dementia of Alzheimer's type. Male Swiss mice received bilateral intracerebroventricular injections of streptozotocin (STZ, 3 mg/kg) dissolved in artificial cerebrospinal fluid. Two days after the first STZ administration, injections were repeated, and the animals were treated with the A3 receptor agonist, CF102 (200 μg/kg intraperitoneally), or vehicle (2% DMSO in saline), 1 h after surgery and once a day until the last day of behavioral evaluation (18 th after the first STZ injection). The animals subjected to STZ administration showed significant recognition memory deficits evaluated by the object recognition task, spatial memory deficits evaluated by water maze test, and early and late memory deficits in the passive avoidance test. No differences of locomotor activity in the open field test were observed between groups. STZ also increased malonaldehyde and nitrite contents in the hippocampus. The treatment with CF102 significantly prevented the early and late memory deficits and object recognition memory deficits. CF102 treatment also reduced the increase of nitrite production in 37% in the hippocampus when compared to STZ group. These data highlight the therapeutic potential of A3 agonists in AD, however the role of these receptors on STZ‐induced AD model requires more investigation. Support or Funding Information Supported by Brazilian National Research and Development Council (CNPq), Coordination for the Improvement of Higher Education Personnel (CAPES) ‐ Brazil, and the Research Support Foundation of Ceará (FUNCAP) – Brazil . This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .